Site Group Page (LTP records: Sites observed with LTP technologies)
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
HomeAbout PhosphoSiteUsing PhosphoSiteprivacy & cookiesCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Site Group Page (LTP records: Sites observed with LTP technologies)

Site Information
HER3 (human) Y1289-p CPAsEQGyEEMRAFQ Links 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17
HER3 (mouse) Y1286-p CPAAEQGyEEMRAFQ Links 13
HER3 (rat) Y1286-p CPAAEQGyEEMRAFQ Links 18



Booth L, et al. (2016) The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget 7, 19620-30
26934000   Curated Info


Safavi S, et al. (2016) HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget 7, 433-45
26595521   Curated Info


Jhaveri TZ, et al. (2015) AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. Oncotarget 6, 14754-65
26143491   Curated Info


Tzouros M, et al. (2013) Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics. Mol Cell Proteomics 12, 3339-49
23882028   Curated Info


Smirnova T, et al. (2012) Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 31, 706-15
21725367   Curated Info


Liu X, et al. (2011) A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res 17, 7127-38
21918175   Curated Info


Takahashi F, et al. (2011) Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30, 3084-95
21339742   Curated Info


Donev IS, et al. (2011) Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17, 2260-9
21220474   Curated Info


Zhang S, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17, 461-9
21399647   Curated Info


Frederick MJ, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178, 548-71
21281788   Curated Info


Chandarlapaty S, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71
21215704   Curated Info


Sheng Q, et al. (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17, 298-310
20227043   Curated Info


Bhuvaneswari R, Gan YY, Soo KC, Olivo M (2009) Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 8, 94
19878607   Curated Info


Monje PV, Athauda G, Wood PM (2008) Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. J Biol Chem 283, 34087-100
18799465   Curated Info


Zhou BB, et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10, 39-50
16843264   Curated Info


Wang SE, et al. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10, 25-38
16843263   Curated Info


Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1, 2005.0008
16729043   Curated Info


Hellyer NJ, Kim MS, Koland JG (2001) Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem 276, 42153-61
11546794   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.